Search results for "Drug targeting"

showing 7 items of 7 documents

Core-crosslinked polymeric micelles: Principles, preparation, biomedical applications and clinical translation

2015

Polymeric micelles (PM) are extensively used to improve the delivery of hydrophobic drugs. Many different PM have been designed and evaluated over the years, and some of them have steadily progressed through clinical trials. Increasing evidence suggests, however, that for prolonged circulation times and for efficient EPR-mediated drug targeting to tumors and to sites of inflammation, PM need to be stabilized, to prevent premature disintegration. Core-crosslinking is among the most popular methods to improve the in vivo stability of PM, and a number of core-crosslinked polymeric micelles (CCPM) have demonstrated promising efficacy in animal models. The latter is particularly true for CCPM in…

DrugDrug targetingMaterials sciencemedia_common.quotation_subjectBiomedical EngineeringMedicine (miscellaneous)Pharmaceutical ScienceNanotechnologyBioengineeringMicelleArticleMaterials Science(all)In vivoGeneral Materials SciencePharmaceutical sciencesPolymermedia_commonMETIS-315279Translation (biology)3. Good healthNanomedicineTargeted drug deliveryIR-99653Drug deliveryNanomedicineCore-crosslinkingEPRMicelleBiotechnologyNano Today
researchProduct

Tailoring the physicochemical properties of core-crosslinked polymeric micelles for pharmaceutical applications.

2016

To optimally exploit the potential of (tumor-) targeted nanomedicines, platform technologies are needed in which physicochemical and pharmaceutical properties can be tailored according to specific medical needs and applications. We here systematically customized the properties of core-crosslinked polymeric micelles (CCPM). The micelles were based on mPEG-b-pHPMAmLacn (i.e. methoxy poly(ethylene glycol)-b-poly[N-(2-hydroxypropyl) methacrylamide-lactate]), similar to the block copolymer composition employed in CriPec® docetaxel, which is currently in phase I clinical trials. The CCPM platform was tailored with regard to size (30 to 100 nm), nanocarrier degradation (1 month to 1 year) and drug…

Drug targetingPolymersPharmaceutical ScienceNanotechnology02 engineering and technologyDocetaxel010402 general chemistry01 natural sciencesMicellechemistry.chemical_compoundCopolymerMicelleschemistry.chemical_classificationAcrylamidesDrug CarriersPolymerDrug release021001 nanoscience & nanotechnology0104 chemical sciencesMolecular WeightDrug LiberationNanomedicineCross-Linking ReagentschemistryTargeted drug deliveryDoxorubicin2023 OA procedureNanomedicinePolymeric micellesTaxoidsCore-crosslinkingNanocarriers0210 nano-technologyDrug carrierEthylene glycolJournal of controlled release : official journal of the Controlled Release Society
researchProduct

Hydrogels for potential colon drug release by thiol-ene conjugate addition of a new inulin derivative.

2008

Inulin was chosen as a starting polymer for biocompatible, pH-sensitive and biodegradable hydrogels. Three INUDVSA-TT hydrogels were obtained by crosslinking inulin derivatives with trimethylolpropane tris(3-mercaptopropionate) under varying conditions. The resulting hydrogels were cell compatible, as demonstrated by MTS and trypan blue exclusion assays acting on Caco-2 cells, and were biodegraded by inulinase and esterase, thus suggesting their use as colonic drug delivery systems. 2-Methoxyestradiol, an anti-cancer drug, was soaked in INUDVSA-TT hydrogels and its in vitro release and apoptotic effect on Caco-2 cells were evaluated.

Succinic AnhydridesPolymers and PlasticsCell SurvivalColonInulinBioengineeringmacromolecular substancesDNA Fragmentationcomplex mixturesBiomaterialschemistry.chemical_compoundDrug Delivery SystemsMaterials ChemistryOrganic chemistryHumansSulfhydryl CompoundsSulfonesHYDROGELS INULIN DRUG TARGETING COLON DELIVERYTrimethylolpropaneParticle SizeEstradioltechnology industry and agricultureInulinHydrogelsCombinatorial chemistry2-MethoxyestradiolMolecular WeightCross-Linking ReagentschemistrySettore CHIM/09 - Farmaceutico Tecnologico ApplicativoSelf-healing hydrogelsDrug deliveryBisbenzimidazoleLiberationTrypan blueCaco-2 CellsDrug carrierBiotechnologyConjugateMacromolecular bioscience
researchProduct

Role of Myeloid-Epithelial-Reproductive Tyrosine Kinase and Macrophage Polarization in the Progression of Atherosclerotic Lesions Associated With Non…

2019

Recent lines of evidence highlight the involvement of myeloid-epithelial-reproductive tyrosine kinase (MerTK) in metabolic disease associated with liver damage. MerTK is mainly expressed in anti-inflammatory M2 macrophages where it mediates transcriptional changes including suppression of proinflammatory cytokines and enhancement of inflammatory repressors. MerTK is regulated by metabolic pathways through nuclear sensors including LXRs, PPARs, and RXRs, in response to apoptotic bodies or to other sources of cholesterol. Nonalcoholic fatty liver disease (NAFLD) is one of the most serious public health problems worldwide. It is a clinicopathological syndrome closely related to obesity, insuli…

Drug targeting0301 basic medicineMacrophageMacrophage polarizationInflammationReviewMonocyteProinflammatory cytokine03 medical and health sciencesMerTK0302 clinical medicineFibrosisNonalcoholic fatty liver diseasemedicineNonalcoholic fatty liver diseaseMacrophagePharmacology (medical)InflammationPharmacologybusiness.industrylcsh:RM1-950Lipid metabolismMERTKmedicine.diseasemacrophagesAtherosclerosis; Drug targeting; Inflammation; Macrophages; MerTK; Monocytes; Nonalcoholic fatty liver diseaselcsh:Therapeutics. Pharmacology030104 developmental biologyAtherosclerosi030220 oncology & carcinogenesisCancer researchatherosclerosismedicine.symptommonocytesbusinessFrontiers in Pharmacology
researchProduct

SYNTHESIS, CHARACTERIZATION AND IN VITRO CYTOTOXICITY STUDIES OF A MACROMOLECULAR CONJUGATE OF PACLITAXEL BEARING OXYTOCIN AS TARGETING MOIETY.

2007

The present study describes the experimental synthetic procedure and the characterization of a new polyaspartamide macromolecular prodrug of paclitaxel, bearing oxytocin residues as targeting moieties. In vitro stability studies of bioconjugate, performed in media mimicking biological fluids (buffer solutions at pH 7.4 and 5.5) and in human plasma, evidenced the high stability of the targeting portion (oxytocin)-polymer linkage and the ability of this conjugate to release linked paclitaxel in a prolonged way in plasma. Moreover, preliminary in vitro antiproliferative studies, carried out on MCF-7 cells, that are oxytocin receptor positive cells, showed that the polymeric conjugate has the s…

Time FactorsChemistry PharmaceuticalDrug CompoundingpolyaspartamidePharmaceutical ScienceBreast NeoplasmsPolyethylene Glycolschemistry.chemical_compoundpaclitaxelDrug StabilityCell Line TumoroxytocinHumansMoietyProdrugsbioconjugateCytotoxicityCell ProliferationDrug CarriersDose-Response Relationship DrugMolecular StructureHydrolysisdrug targetingGeneral MedicineHydrogen-Ion ConcentrationAntineoplastic Agents PhytogenicOxytocin receptorIn vitroSolubilityPaclitaxelchemistryBiochemistryTargeted drug deliveryReceptors OxytocinDelayed-Action PreparationsFemalePeptidesDrug carrierBiotechnologyConjugate
researchProduct

Polymer-based systems for controlled release and targeting of drugs

2019

The current need to find new advanced approaches to carry biologically active substances (conventional organic drugs, peptides, proteins (such as antibodies), and nucleic acid-based drugs (NABDs such as siRNA and miRNA)) in the body fluids, to realize targeted therapies and even personalized ones, goes hand in hand with research on the performance of new materials to better realize appropriate drug vectors [...]

Drugchemistry.chemical_classificationPolymers and PlasticsChemistrymedia_common.quotation_subjectNew materialspolymers drug release drug targetingGeneral ChemistryComputational biologyPolymerControlled releaseEditorialNucleic acidBiologically active substancesmedia_common
researchProduct

The antifibrotic potential of a sustained release formulation of a PDGF beta-receptor targeted rho kinase inhibitor

2019

Rho kinase activity in hepatic stellate cells (HSCs) is associated with activation, transformation and contraction of these cells, leading to extracellular matrix production and portal hypertension in liver cirrhosis. Inhibition of rho kinase activity can reduce these activities, but may also lead to side effects, for instance systemic hypotension. This can be circumvented by liver-specific delivery of a rho kinase inhibitor to effector cells. Therefore, we targeted the rho kinase inhibitor Y27632 to the key pathogenic cells in liver fibrosis, i.e. myofibroblasts including activated HSCs that highly express the PDGF beta-receptor, using the drug carrier pPB-MSA. This carrier consists of mou…

Liver CirrhosisDrug targetingPyridinesPolymeric microspheresPharmaceutical Science02 engineering and technologyPharmacologychemistry.chemical_compoundY-27632FibrosisControlled releaseRho-associated protein kinaseMice Knockout0303 health sciencesDrug Carriersrho-Associated KinasesChemistryCIRRHOTIC RATS021001 nanoscience & nanotechnologyMicrospheresY-27632Drug deliveryFemale0210 nano-technologyDrug carrierATP Binding Cassette Transporter Subfamily BSIGNALING CONTRIBUTESLiver fibrosisBiologicalsHEPATIC STELLATE CELLSCell LineMECHANISMSReceptor Platelet-Derived Growth Factor beta03 medical and health sciencesDELIVERYROCK INHIBITORmedicineAnimalsHumansProtein Kinase Inhibitors030304 developmental biologyProtein deliveryPORTAL PRESSUREmedicine.diseaseAmidesTargeted drug deliveryRho kinase inhibitorDelayed-Action PreparationsHepatic stellate cellVASODILATIONJournal of Controlled Release
researchProduct